Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 12;14(10):3349.
doi: 10.3390/jcm14103349.

Renal and Safety Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study

Junhyuk Chang  1 , Chungsoo Kim  2   3 , Heejung Choi  4 , Rae Woong Park  1   5 , Sukhyang Lee  6
Affiliations

Renal and Safety Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study

Junhyuk Chang et al. J Clin Med. .

Abstract

Background/Objectives: Evidence on the renal benefits and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Asia region is still lacking. This study aimed to evaluate the renal and safety outcomes of SGLT2is compared with dipeptidyl peptidase-4 inhibitors (DPP4i) using real-world data. Methods: A retrospective cohort study was conducted using the nationwide claims data in Republic of Korea. We evaluated kidney outcomes (any new-onset kidney events, acute kidney injury (AKI), chronic kidney disease (CKD), and kidney failure) as primary outcomes and safety outcomes (infection, hemodynamic adverse events, and fracture). Propensity score matching was used to adjust confounders, and the hazard ratios were calculated using the Cox proportional hazards model. Results: The study included 13,649 patients in the SGLT2i group and 35,043 in the DPP4i group after the matching. The SGLT2i group had a lower risk of kidney diseases, AKI, and CKD (HR 0.88 [0.61-0.74]) than the DPP4i group. For secondary outcomes, the risk of genital infection was higher (HR 2.38 [2.12-2.68]), and the risk of hyperkalemia was lower in the SGLT2i group than in the DPP4i group (HRs 0.49 [0.36-0.67]). Conclusions: The SGLT2 inhibitors had a lower risk of new-onset kidney outcomes and CKD than the DPP4 inhibitors. A high incidence of genital infection and a low incidence of hyperkalemia were shown in the SGLT2 inhibitor.

Keywords: cardiovascular disease; dipeptidyl peptidase IV inhibitor; kidney disease; sodium–glucose transporter 2 inhibitor; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Kaplan–Meier plot of the outcomes estimated from the main analysis setting that compared the SGLT2i group versus the DPP4i group. SGLT2i: sodium–glucose cotransporter 2 inhibitor; DPP4i: dipeptidyl peptidase-4 inhibitor.
Figure 2
Figure 2
Forest plots of the outcomes estimated from sensitivity analysis setting that compared the SGLT2i group versus the DPP4i group. SGLT2i: sodium–glucose cotransporter 2 inhibitor; DPP4i: dipeptidyl peptidase-4 inhibitor. * Statistically significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720. - DOI - PubMed
    1. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Silverman M.G., Zelniker T.A., Kuder J.F., Murphy S.A., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389. - DOI - PubMed
    1. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744. - DOI - PubMed
    1. Heerspink H.J., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., Mann J.F.E., McMurray J.J.V., Lindberg M., Rossing P., et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816. - DOI - PubMed
    1. Heerspink H.J.L., Karasik A., Thuresson M., Melzer-Cohen C., Chodick G., Khunti K., Wilding J.P.H., Rodriguez L.A.G., Cea-Soriano L., Kohsaka S., et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27–35. doi: 10.1016/S2213-8587(19)30384-5. - DOI - PubMed

LinkOut - more resources